vimarsana.com

பெருநிறுவன தகவல்தொடர்புகள் டெபிட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DIC Invests in Israeli Biotech Startup Vaxa Technologies

Press release content from Business Wire. The AP news staff was not involved in its creation. DIC Invests in Israeli Biotech Startup Vaxa Technologies April 28, 2021 GMT TOKYO (BUSINESS WIRE) Apr 28, 2021 DIC Corporation (TOKYO:4631) has completed investment in Vaxa Technologies Ltd., a biotech startup headquartered in Rosh Pina, Israel, as part of a strategic expansion of DIC businesses around health food and other algae-derived products. Vaxa Technologies possesses unique proprietary light-emitting diode (LED) illuminated photobioreactors and algae cultivation technologies and is engaged in the development and commercialization of clean, unparalleled high-value-added algae products. Vaxa Technologies’ cultivation process employs renewable energy, achieving excellent productivity while consuming significantly less land and fresh water than conventional cultivation methods. This process also converts discharged CO2 into useful materials, making the process carbon negative and

Chugai Pharmaceutical Co , Ltd : CHMP Recommends EU Approval of Chugai s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Chugai Pharmaceutical Co , Ltd : CHMP Recommends EU Approval of Chugai s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

CHMP Recommends EU Approval of Chugais Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

CHMP Recommends EU Approval of Chugais Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.